A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas

[1] Shankland KR(2012)Non-Hodgkin lymphoma Lancet 380 848-857

[2] Armitage JO(1997)Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification Ann Oncol 8 583-592

[3] Hancock BW(2006)Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001 Blood 107 265-276

[4] Ascani S(2014)Differences in incidence and trends of haematological malignancies in Japan and the United States Br J Haematol 164 536-545

[5] Zinzani PL(2014)Peripheral T cell lymphoma in Asia Int J Hematol 99 227-239

[6] Gherlinzoni F(2016)The 2016 revision of the World Health Organization classification of lymphoid neoplasms Blood 127 2375-2390

[7] Morton LM(2008)International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes J Clin Oncol 26 4124-4130

[8] Wang SS(2014)Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry Blood 124 1570-1577

[9] Devesa SS(2010)Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin Lymphoma Study Group Blood 116 3418-3425

[10] Chihara D(2009)High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German high-grade non-Hodgkin Lymphoma Study Group (DSHNHL) Ann Oncol 20 1977-1984

[1] Shankland KR(2012)Non-Hodgkin lymphoma Lancet 380 848-857

[2] Armitage JO(1997)Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification Ann Oncol 8 583-592

[3] Hancock BW(2006)Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001 Blood 107 265-276

[4] Ascani S(2014)Differences in incidence and trends of haematological malignancies in Japan and the United States Br J Haematol 164 536-545

[5] Zinzani PL(2014)Peripheral T cell lymphoma in Asia Int J Hematol 99 227-239

[6] Gherlinzoni F(2016)The 2016 revision of the World Health Organization classification of lymphoid neoplasms Blood 127 2375-2390

[7] Morton LM(2008)International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes J Clin Oncol 26 4124-4130

[8] Wang SS(2014)Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry Blood 124 1570-1577

[9] Devesa SS(2010)Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin Lymphoma Study Group Blood 116 3418-3425

[10] Chihara D(2009)High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German high-grade non-Hodgkin Lymphoma Study Group (DSHNHL) Ann Oncol 20 1977-1984